Home > Insider Trading > Filing (0001104659-21-076488)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1006281	Protalix Biotherapeutics Inc.	PLX	Biological Products, (No Disgnostic Substances) (2836)	650643773

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1636701	Dan Oren	1 Dexcel Street Or Akiva L3 3060000		No	No	Yes	No
1720007	Ltd. Technologies Pharma Dexcel	10 Hakidma Street Yokneam L3 2069200		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-06-02	61,211	$2.56	4,494,820	No	4	S	Direct
Common Stock	Disposition	2021-06-03	857,506	$2.25	3,637,314	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.
The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive.
The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive.
The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.